New advances in heart failure therapy
Keywords:
heart failure, neprilysin, isosorbide dinitrateAbstract
Heart diseases are a topic frequently treated in medical researches, due to their wide repercussion on the functioning of the human body; therefore, the study of the treatment of these organ affections is highlighted, being an important task to maintain and enhance knowledge about therapeutic advances in diseases related to it. This work is carried out with the aim of describing the advances in heart failure therapy. A review of the scientific publications of the last two years was performed. Although there are differences regarding the proposed therapy for heart failure, the American and European Associations of cardiology firmly establish the quadruple therapy (with angiotensin receptor inhibitors neprilysin, ß-blockers; mineralocorticoids antagonist receptors and glucose/sodium cotransporters-2 inhibitors—targeted at heart failure with reduced ejection fraction—, the recommendation of isosorbide dinitrate/hydralazine for black patients, and the use of implantable cardioversion in the prevention of the sudden death. It is concluded that the harmonization of these guidelines, in both continents, provides a unique treatment for heart failure, although it needs additional study in patients with normal left ventricular ejection fraction.
Downloads
Download data is not yet available.
References
1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J [Internet]. 2021 [citado 25/09/2023];42(36):3599-726. Disponible en: https://academic.oup.com/eurheartj/article/42/36/3599/6358045
2. Bozkurt B. It Is Time to Screen for Heart Failure: Why and How? JACC Heart Fail [Internet]. 2022 [citado 25/09/2023];10(8):598-600. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jchf.2022.06.001
3. Espinosa B, Llorens P, Gil V, et al. Pronóstico de la insuficiencia cardíaca aguda basado en datos clínicos de congestión. Rev Clín Esp [Internet]. 2022 [citado 25/09/2023];222(6):321-31. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014256521001582
4. Burgos LM, Coronel ML, Thierer J. Actitudes y prácticas clínicas en la insuficiencia cardiaca en médicos de Argentina. Rev Arg Cardiol [Internet]. 2022 [citado 25/09/2023];90:203-14. Disponible en: http://www.old2.sac.org.ar/wp-content/uploads/2022/07/v90n3a07-1.pdf
5. Thierer J, Perna ER, Marino J, et al. Insuficiencia cardíaca crónica en Argentina. OFFICE IC AR, un registro conjunto de la Sociedad Argentina de Cardiología y de la Federación Argentina de Cardiología. Rev Fed Arg Cardiol [Internet]. 2022 [citado 25/09/2023];51(1):37-44. Disponible en: https://www.revistafac.org.ar/ojs/index.php/revistafac/article/view/365
6. Rodríguez-León A, Izquierdo-Medina R, Garcés-González R, et al. Superación sobre cuidados paliativos en pacientes con insuficiencia cardiaca crónica. Edumecentro [Internet]. 2022 [citado 31/10/2023];14:e2115. Disponible en: https://revedumecentro.sld.cu/index.php/edumc/article/view/e2115
7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023];79(17):e263-421. Disponible en: https://www.jacc.org/doi/abs/10.1016/j.jacc.2021.12.012
8. Yifang GUO. Interpretation of the Essential Updatesin 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Chinese Gen Pract [Internet]. 2022 [citado 25/09/2023];25(17):2051. Disponible en: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0288
9. Morris AA, Butler J. Updated Heart Failure Guidelines: Time for a Refresh. Circulation [Internet]. 2022 [citado 25/09/2023];145(18):1371-3. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.122.059104
10. Díaz R, Díaz J, Fuenmayor Ojeda V, et al. Insuficiencia cardíaca aguda: análisis clínico epidemiológico. Med Interna (Caracas) [Internet]. 2018 [citado 15/01/2023];34(4):224-36. Disponible en: https://www.svmi.web.ve/wp-content/uploads/2022/07/V34_N4.pdf#page=39
11. Li D, Zheng C, Zhao J, et al. Diagnosis of heart failure from imbalance datasets using multi-level classification. Biomed Signal Process Control [Internet]. 2023 [citado 10/03/2023];81:104538. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1746809422009922
12. Santulli G, Wang X, Mone P. Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what's new? from epidemiology to clinical management. Eur Heart J Cardiovasc Pharmacother [Internet]. 2022 [citado 25/09/2023];8(5):e23-4. Disponible en: https://academic.oup.com/ehjcvp/article/8/5/e23/6572834
13. Basantes Orbea AB, Carrillo López VA, Aguilar Cobo AV, et al. Insuficiencia cardiaca, diagnóstico y tratamiento. Recimundo [Internet]. 2022 [citado 25/09/2023];6(1):34-50. Disponible en: https://recimundo.com/index.php/es/article/view/1498
14. Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis? J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023];80(6):595-7. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jacc.2022.05.028
15. Zamorano JL, Manzano L, Comín-Colet J, et al. Retos en el abordaje de pacientes con insuficiencia cardiaca y fracción de eyección reducida. Rev Esp Cardiol Supl [Internet]. 2022 [citado 25/09/2023];22:1-7. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1131358722000012
16. Bayés‐Genís A, Aimo A, Metra M, et al. Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines. Eur J Heart Fail [Internet]. 2022 [citado 25/09/2023];24(6):916-26. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2542
17. Baldewijns K, Boyne J, Rohde C, et al. What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions. Heart Lung [Internet]. 2023 [citado 10/03/2023];57:25-30. Disponible en: https://www.sciencedirect.com/science/article/pii/S0147956322001765
18. Savarese G, Kishi T, Vardeny O, et al. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail [Internet]. 2023 [citado 10/03/2023];11(1):1-14. Disponible en: https://www.jacc.org/doi/abs/10.1016/j.jchf.2022.08.009
19. Kaneko T, Kagiyama N, Nakamura Y, et al. External validation of the ACUTE HF score for risk stratification in acute heart failure. Int J Cardiol [Internet]. 2023 [citado 10/03/2023];370:396-401. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0167527322016412
20. Heckman GA, Rockwood K. Frailty, Risk, and Heart Failure Care: Commission or Omission? J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023]; 80(12):1144–6. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jacc.2022.07.007
21. Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol [Internet]. 2022 [citado 25/09/2023];45:S31-9. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23846
22. Hamid A, Handelsman Y, Butler J. DCRM Multispecialty Recommendations in Patients with Heart Failure: For Special Issue on Cardio-Renal-Metabolism. J Card Fail [Internet]. 2022 [citado 25/09/2023];28(11):1642-5. Disponible en: https://www.onlinejcf.com/article/S1071-9164(22)00674-1/fulltext
23. De Maria R, Gori M, Marini M, et al. Tendencias temporales en las características, tratamiento y resultados de la insuficiencia cardiaca en octogenarios durante dos décadas. Rev Esp Cardiol [Internet]. 2022 [citado 25/09/2023];75(11):886-96. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0300893222000677
24. Fernández-Bergés D, González-Fernández R, Félix-Redondo FJ, et al. Evolución del perfil clínico y pronóstico de pacientes con alta hospitalaria por insuficiencia cardíaca en las dos primeras décadas del siglo XXI. El Registro INCA-Ex. Aten Primaria [Internet]. 2022 [citado 25/09/2023];54(7):102357. Disponible en: https://www.sciencedirect.com/science/article/pii/S0212656722000774
25. Muhammed A, Abdelazeem M, Elewa MG, et al. Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction. Heart Fail Rev [Internet]. 2022 [citado 25/09/2023];28(1):229-40. Disponible en: https://link.springer.com/article/10.1007/s10741-022-10246-6
26. Rathod VS, Stiles M. Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2022;24(7):123-36. DOI: 10.1007/s11936-022-00962-5.
27. Bueno H, Bernal JL, Jiménez-Jiménez V, et al. The clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. Rev Esp Cardiol (Engl Ed) [Internet]. 2022 [citado 25/09/2023];75(7):585-94. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1885585721002590
28. Belkin MN, Cifu AS, Pinney S. Management of Heart Failure. JAMA [Internet]. 2022 [citado 25/09/2023];328(13):1346-7. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2796605
29. Zheng J, Tisdale RL, Heidenreich PA, et al. Disparities in hospital length of stay across race and ethnicity among patients with heart failure. Circ Heart Fail [Internet]. 2022 [citado 25/09/2023];15(11):e009362. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/CIRCHEARTFAILURE.121.009362
2. Bozkurt B. It Is Time to Screen for Heart Failure: Why and How? JACC Heart Fail [Internet]. 2022 [citado 25/09/2023];10(8):598-600. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jchf.2022.06.001
3. Espinosa B, Llorens P, Gil V, et al. Pronóstico de la insuficiencia cardíaca aguda basado en datos clínicos de congestión. Rev Clín Esp [Internet]. 2022 [citado 25/09/2023];222(6):321-31. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014256521001582
4. Burgos LM, Coronel ML, Thierer J. Actitudes y prácticas clínicas en la insuficiencia cardiaca en médicos de Argentina. Rev Arg Cardiol [Internet]. 2022 [citado 25/09/2023];90:203-14. Disponible en: http://www.old2.sac.org.ar/wp-content/uploads/2022/07/v90n3a07-1.pdf
5. Thierer J, Perna ER, Marino J, et al. Insuficiencia cardíaca crónica en Argentina. OFFICE IC AR, un registro conjunto de la Sociedad Argentina de Cardiología y de la Federación Argentina de Cardiología. Rev Fed Arg Cardiol [Internet]. 2022 [citado 25/09/2023];51(1):37-44. Disponible en: https://www.revistafac.org.ar/ojs/index.php/revistafac/article/view/365
6. Rodríguez-León A, Izquierdo-Medina R, Garcés-González R, et al. Superación sobre cuidados paliativos en pacientes con insuficiencia cardiaca crónica. Edumecentro [Internet]. 2022 [citado 31/10/2023];14:e2115. Disponible en: https://revedumecentro.sld.cu/index.php/edumc/article/view/e2115
7. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023];79(17):e263-421. Disponible en: https://www.jacc.org/doi/abs/10.1016/j.jacc.2021.12.012
8. Yifang GUO. Interpretation of the Essential Updatesin 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Chinese Gen Pract [Internet]. 2022 [citado 25/09/2023];25(17):2051. Disponible en: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0288
9. Morris AA, Butler J. Updated Heart Failure Guidelines: Time for a Refresh. Circulation [Internet]. 2022 [citado 25/09/2023];145(18):1371-3. Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.122.059104
10. Díaz R, Díaz J, Fuenmayor Ojeda V, et al. Insuficiencia cardíaca aguda: análisis clínico epidemiológico. Med Interna (Caracas) [Internet]. 2018 [citado 15/01/2023];34(4):224-36. Disponible en: https://www.svmi.web.ve/wp-content/uploads/2022/07/V34_N4.pdf#page=39
11. Li D, Zheng C, Zhao J, et al. Diagnosis of heart failure from imbalance datasets using multi-level classification. Biomed Signal Process Control [Internet]. 2023 [citado 10/03/2023];81:104538. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1746809422009922
12. Santulli G, Wang X, Mone P. Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what's new? from epidemiology to clinical management. Eur Heart J Cardiovasc Pharmacother [Internet]. 2022 [citado 25/09/2023];8(5):e23-4. Disponible en: https://academic.oup.com/ehjcvp/article/8/5/e23/6572834
13. Basantes Orbea AB, Carrillo López VA, Aguilar Cobo AV, et al. Insuficiencia cardiaca, diagnóstico y tratamiento. Recimundo [Internet]. 2022 [citado 25/09/2023];6(1):34-50. Disponible en: https://recimundo.com/index.php/es/article/view/1498
14. Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis? J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023];80(6):595-7. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jacc.2022.05.028
15. Zamorano JL, Manzano L, Comín-Colet J, et al. Retos en el abordaje de pacientes con insuficiencia cardiaca y fracción de eyección reducida. Rev Esp Cardiol Supl [Internet]. 2022 [citado 25/09/2023];22:1-7. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1131358722000012
16. Bayés‐Genís A, Aimo A, Metra M, et al. Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA Heart Failure Guidelines. Eur J Heart Fail [Internet]. 2022 [citado 25/09/2023];24(6):916-26. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2542
17. Baldewijns K, Boyne J, Rohde C, et al. What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions. Heart Lung [Internet]. 2023 [citado 10/03/2023];57:25-30. Disponible en: https://www.sciencedirect.com/science/article/pii/S0147956322001765
18. Savarese G, Kishi T, Vardeny O, et al. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail [Internet]. 2023 [citado 10/03/2023];11(1):1-14. Disponible en: https://www.jacc.org/doi/abs/10.1016/j.jchf.2022.08.009
19. Kaneko T, Kagiyama N, Nakamura Y, et al. External validation of the ACUTE HF score for risk stratification in acute heart failure. Int J Cardiol [Internet]. 2023 [citado 10/03/2023];370:396-401. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0167527322016412
20. Heckman GA, Rockwood K. Frailty, Risk, and Heart Failure Care: Commission or Omission? J Am Coll Cardiol [Internet]. 2022 [citado 25/09/2023]; 80(12):1144–6. Disponible en: https://www.jacc.org/doi/full/10.1016/j.jacc.2022.07.007
21. Talha KM, Butler J. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. Clin Cardiol [Internet]. 2022 [citado 25/09/2023];45:S31-9. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23846
22. Hamid A, Handelsman Y, Butler J. DCRM Multispecialty Recommendations in Patients with Heart Failure: For Special Issue on Cardio-Renal-Metabolism. J Card Fail [Internet]. 2022 [citado 25/09/2023];28(11):1642-5. Disponible en: https://www.onlinejcf.com/article/S1071-9164(22)00674-1/fulltext
23. De Maria R, Gori M, Marini M, et al. Tendencias temporales en las características, tratamiento y resultados de la insuficiencia cardiaca en octogenarios durante dos décadas. Rev Esp Cardiol [Internet]. 2022 [citado 25/09/2023];75(11):886-96. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0300893222000677
24. Fernández-Bergés D, González-Fernández R, Félix-Redondo FJ, et al. Evolución del perfil clínico y pronóstico de pacientes con alta hospitalaria por insuficiencia cardíaca en las dos primeras décadas del siglo XXI. El Registro INCA-Ex. Aten Primaria [Internet]. 2022 [citado 25/09/2023];54(7):102357. Disponible en: https://www.sciencedirect.com/science/article/pii/S0212656722000774
25. Muhammed A, Abdelazeem M, Elewa MG, et al. Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction. Heart Fail Rev [Internet]. 2022 [citado 25/09/2023];28(1):229-40. Disponible en: https://link.springer.com/article/10.1007/s10741-022-10246-6
26. Rathod VS, Stiles M. Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy. Curr Treat Options Cardiovasc Med. 2022;24(7):123-36. DOI: 10.1007/s11936-022-00962-5.
27. Bueno H, Bernal JL, Jiménez-Jiménez V, et al. The clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. Rev Esp Cardiol (Engl Ed) [Internet]. 2022 [citado 25/09/2023];75(7):585-94. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1885585721002590
28. Belkin MN, Cifu AS, Pinney S. Management of Heart Failure. JAMA [Internet]. 2022 [citado 25/09/2023];328(13):1346-7. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2796605
29. Zheng J, Tisdale RL, Heidenreich PA, et al. Disparities in hospital length of stay across race and ethnicity among patients with heart failure. Circ Heart Fail [Internet]. 2022 [citado 25/09/2023];15(11):e009362. Disponible en: https://www.ahajournals.org/doi/abs/10.1161/CIRCHEARTFAILURE.121.009362
Downloads
Published
2023-12-02
How to Cite
1.
Arredondo-Rubido AE, Arredondo-Bruce AE. New advances in heart failure therapy. Rev Méd Electrón [Internet]. 2023 Dec. 2 [cited 2025 Jan. 10];45(6):e5259. Available from: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/5259
Issue
Section
Review article
License
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
